Akari Therapeutics, Plc (AKTX) stock profile

Frequently asked questions

What does Akari Therapeutics, Plc (AKTX) do?

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company focused on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. The company is based in London, the United Kingdom.

Where is AKTX stock listed?

Akari Therapeutics, Plc trades under the ticker AKTX on NASDAQ.

How can I research AKTX's financials and filings?

Vantafin provides Akari Therapeutics, Plc's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the AKTX profile.